Cognition Therapeutics, Inc.
$1.12
▼
-2.63%
2026-04-21 06:00:02
www.cogrx.com
NCM: CGTX
Explore Cognition Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$106.33 M
Current Price
$1.12
52W High / Low
$3.83 / $0.22
Stock P/E
—
Book Value
$0.39
Dividend Yield
—
ROCE
-70.77%
ROE
-88.59%
Face Value
—
EPS
$-0.32
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
14
Beta
1.4
Debt / Equity
1.86
Current Ratio
3.45
Quick Ratio
3.45
Forward P/E
-3.02
Price / Sales
—
Enterprise Value
$44.66 M
EV / EBITDA
-0.94
EV / Revenue
—
Rating
Strong Buy
Target Price
$3.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Vivani Medical, Inc. | $1.51 | — | $127.82 M | — | -84.04% | -1.6% | $1.92 / $0.92 | $0.21 |
| 2. | Armata Pharmaceuticals, Inc. | $12.5 | — | $421.28 M | — | -45.96% | 130.37% | $16.34 / $1.11 | $-6 |
| 3. | ImmunityBio, Inc. | $8.01 | — | $8.28 B | — | -58.17% | 71.02% | $12.43 / $1.83 | $-0.49 |
| 4. | Lisata Therapeutics, Inc. | $2.83 | — | $25.56 M | — | -124.1% | -75.53% | $5.07 / $1.81 | $1.68 |
| 5. | Kyverna Therapeutics, Inc. | $11.25 | — | $600.17 M | — | -65.99% | -64.67% | $13.67 / $1.78 | $3.85 |
| 6. | Aurinia Pharmaceuticals Inc. | $15.96 | 7.38 | $2.12 B | — | 16.2% | 59.91% | $16.54 / $7.29 | $4.39 |
| 7. | Verastem, Inc. | $6.52 | — | $557.75 M | — | -97.68% | -14.8% | $11.24 / $4.01 | $0.74 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -3.67 M | -5.16 M | -6.87 M | -8.69 M | -7.69 M | — |
| Net Profit | -3.34 M | -4.93 M | -6.73 M | -8.48 M | -7.84 M | — |
| EPS in Rs | -0.04 | -0.06 | -0.08 | -0.09 | -0.09 | -0.25 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -24.39 M | -34.42 M | -25.92 M | -21.33 M |
| Net Profit | -23.49 M | -33.97 M | -25.79 M | -21.4 M |
| EPS in Rs | -0.26 | -0.38 | -0.29 | -0.24 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 48.39 M | 30.23 M | 35.16 M | 50.42 M |
| Total Liabilities | 14.12 M | 11.48 M | 10.69 M | 10.18 M |
| Equity | 34.27 M | 18.75 M | 24.47 M | 40.25 M |
| Current Assets | 47.99 M | 29.55 M | 34.22 M | 47.65 M |
| Current Liabilities | 13.92 M | 11.14 M | 10.17 M | 7.79 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -24.59 M | -28.47 M | -16.02 M | -18.53 M |
| Investing CF | 0.01 M | -0 M | -0.15 M | -0.17 M |
| Financing CF | 36.57 M | 23.57 M | 4.52 M | 5.55 M |
| Free CF | -24.59 M | -28.48 M | -16.16 M | -18.7 M |
| Capex | — | -0 M | -0.15 M | -0.17 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -31.73% | -20.52% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.